Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284400 | 0.92 | PROKR2 (0.62) | PROKR2MAP3K7TAB1 | |
| SCHEMBL565577 | 0.92 | PROKR2 (0.72) | PROKR2MAP3K7TAB1 | |
| SCHEMBL564805 | 0.92 | PROKR2 (0.72) | PROKR2MAP3K7TAB1 | |
| SCHEMBL565626 | 0.92 | PROKR2 (0.72) | PROKR2MAP3K7TAB1 | |
| SCHEMBL13284338 | 0.91 | PROKR2 (0.61) | PROKR2ADORA2AADORA1MAP3K7TAB1 | |
| SCHEMBL565189 | 0.88 | PROKR2 (0.65) | PROKR2MAP3K7TAB1EIF4E | |
| SCHEMBL10107123 | 0.88 | PROKR2 (0.65) | PROKR2MAP3K7TAB1EIF4E | |
| SCHEMBL10119875 | 0.85 | PROKR2 (0.57) | PROKR2ADORA2AADORA1EIF4E | |
| SCHEMBL10107263 | 0.85 | PROKR2 (0.57) | PROKR2ADORA2AADORA1EIF4E | |
| SCHEMBL565861 | 0.85 | PROKR2 (0.59) | PROKR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885ADORA2A 330/4885ADORA1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.